An Open-Label Study of GS-7977 + Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies
An Open-Label Study of GS-7977 + Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies
This study will evaluate the efficacy, safety, and tolerability of sofosbuvir (SOF; GS-7977) in combination with ribavirin (RBV) with or without pegylated interferon (Peg-IFN) in adults with chronic hepatitis C virus (HCV) infection who participated in a prior Gilead HCV study and have not achieved sustained virologic response (SVR).
Inclusion Criteria:
Infection with HCV
Must have participated in a prior Gilead HCV study
Use of highly effective contraception methods if female of childbearing potential or sexually active male
Eligible patients include those in the following
received placebo or Peg-IFN+RBV in a control arm
previously participated in a Gilead-sponsored HCV study and did not attain sustained virologic response 24 weeks after discontinuation of therapy (SVR24) on a regimen containing:
Exclusion Criteria:
Coronado, California 92118, United States
Bradenton, Florida 34209, United States
Township, New Jersey 08234, United States
Australian Capital Territory, 2605, Australia
NSW, 2050, Australia
Perth Western Australia, 6000, Australia
State of Queensland, 4102, Australia
Victoria, 3128, Australia
Frankfurt am Main, 60590, Germany
Heidelberg, 69120, Germany
San Giovanni Rotonda, Foggia 71013, Italy
Hampshire, SO16 6YD, United Kingdom